CD19 and cancer: Here, we demonstrate that allogeneic CAR T-cells expressing tandem receptors targeting CD19 and NKG2DL show equivalent efficacy to CD19 single-targeting CAR T-cells against CD19+ cancer cell lines and primary B-ALL samples.